Search For
/
Stocks
Intraday Booster
Sector Booster
Stock Screener
Market Pulse
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersMain
Stock Screener
Create Screener
Explore Screeners
Community ScreenersTrading Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNewTechnical Screeners
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMoreMarkets
Global Market Today
Global Indices
Indian Indices
NIfty TodaySmart Money
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataDerivatives
FnO Movements
NSE F&O Lot Size
Ban ListAnalysis & Calendars
Technical DashboardSector Booster
Sector AnalysisNew
Result Calendar
Economic Calendar
Alivus Life Sciences
Mid Cap•2,203 Employees•IPO 2021
Current Price
₹939.40
-10.35 (-1.09%)Updated
Today's Range
925.3
₹939.40
946.75
52 Week Range
52W Low₹819.00
52W High₹1225.10
₹939.40
Downside14.70%
Upside30.41%
Price Chart
Compare with Peers
Historical Ratios
Track top 12 most important financial ratios
P/E Ratio: Price to Earnings - Most used valuation metric
Loading chart...
Analyzing Investment Quality
Processing 9 key metrics...
Key Metrics
Hover for details
Valuation
Market Cap
₹11,095.98 Cr
Market Cap
Total market value of companyP/E Ratio
20.35
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)P/B Ratio
3.78
P/B Ratio
Price to Book Value. <3 may indicate undervaluationEPS
₹44.23
EPS
Earnings Per Share. Higher and growing is positiveProfitability
ROE
9.32%
ROE
Return on Equity. >15% is good, >20% is excellentROCE
-%
ROCE
Return on Capital Employed. >15% is goodNet Margin
21.64%
Net Margin
Net profit as % of revenue. >10% is goodOperating Margin
-%
Operating Margin
Operating profit margin. >15% is goodGrowth
EPS Growth (5Y)
9.11%
EPS Growth (5Y)
5-year EPS growth. >15% is strongRevenue Growth (5Y)
9.20%
Revenue Growth (5Y)
5-year revenue growth. >10% is goodQtr Sales Growth
-%
Qtr Sales Growth
Quarter-over-quarter sales growthQtr Profit Growth
-%
Qtr Profit Growth
Quarter-over-quarter profit growthFinancial Health
Debt/Equity
0.02
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellentBook Value
₹229.94
Book Value
Net asset value per shareDividend Yield
0.55%
Dividend Yield
Annual dividend as % of price. >2% is goodPromoter Holding
74.90%
Promoter Holding
Promoter stake. >50% shows confidenceGood
Average
Needs Attention
SWOT Analysis
Strengths
5 points- •Strong promoter holding (74.9%) indicates management confidence and stable ownership.
- •Virtually debt-free with a low 0.02 debt-to-equity ratio.
Weaknesses
5 points- •Reported 0.00% for ROCE and ROE raises capital efficiency concerns.
- •Zero quarterly sales and profit variation indicates potential short-term stagnation.
Opportunities
5 points- •Positioned in robust Pharmaceuticals/Healthcare sectors, capitalizing on global demand.
- •Increasing DII holding (1.41% to 5.62%) signals growing institutional confidence.
Threats
5 points- •Intense competition from larger players limits market share and pricing power.
- •Highly regulated industry poses risks from changing policies and compliance costs.
Segment-wise Financial Analysis
Fetching Financials...
Fetching Balance Sheet...
Fetching Cash Flow...
Shareholding Pattern
Loading shareholding data...
Company Insider Trading Activity
No insider trading data available
Corporate Action
Company Announcements
Technical Analysis & Indicators
Standard pivot points - most widely used
Pivot Points (CLASSIC)
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹991.90 | +₹52.50 | +5.59% |
| R3 | ₹970.45 | +₹31.05 | +3.31% |
| R2 | ₹958.60 | +₹19.20 | +2.04% |
| R1 | ₹949.00 | +₹9.60 | +1.02% |
| PIVOT | ₹937.15 | -2.25 | -0.24% |
| CURRENT | ₹939.40 | - | - |
| S1 | ₹884.65 | -₹54.75 | -5.83% |
| S2 | ₹906.10 | -₹33.30 | -3.54% |
| S3 | ₹915.70 | -₹23.70 | -2.52% |
| S4 | ₹927.55 | -₹11.85 | -1.26% |
CPR Levels
Support
Resistance
S4
N/A
S3
N/A
S2
N/A
S1
N/A
| CPR |
BC: N/AP: N/ATC: N/A
R1
N/A
R2
N/A
R3
N/A
R4
N/A
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment
is trading CPR, indicating
● CPR Width
CPR is
● Opening Range
Day's range: ~
● Price Position
Trading Inside opening range
Delivery Volume Analysis & Trading Activity
Latest Volume-56.1% vs avg
0.25L
(12 Mar 2026)Delivery %-0.9% vs avg
52.4%
(12 Mar 2026)Avg Volume (20D)20-day average
0.57L
(12 Feb - 12 Mar)Avg Delivery %Trend ↑
53.4%
(12 Feb - 12 Mar)Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.
Peer Comparison & Industry Benchmarking
Quick Compare
Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Procter & Gamble Health Ltd
158.00 %
Highest Dividend Yield
Procter & Gamble Health Ltd
3.64 %
Peer Comparison
| Company Name |
|---|
 Acutaas Chemicals Ltd |
 Aether Industries Ltd |
 Blue Jet Healthcare Ltd |
 Caplin Point Laboratories Ltd |
 Cohance Lifesciences Ltd |
 Concord Biotech Ltd |
 Granules India Ltd |
 Marksans Pharma Ltd |
 Natco Pharma Ltd |
 Procter & Gamble Health Ltd |
 |
 Sanofi India Ltd |
 Sanofi Consumer Healthcare India Ltd |
 Strides Pharma Science Ltd |
 Sun Pharmaceutical Industries Ltd |
About
Alivus Life Sciences Ltd
Alivus Life Sciences Limited, formerly known as Glenmark Life Sciences Limited, is an Indian pharmaceutical company specializing in the development, manufacturing, and marketing of non-commoditized Active Pharmaceutical Ingredients (APIs). These APIs are crucial components used in the production of various finished dosage forms of medications.
The company's portfolio encompasses a wide range of APIs targeting diverse therapeutic areas. This includes cardiovascular disease treatments (like olmesartan, telmisartan, and perindopril), central nervous system disorder medications (zonisamide), diabetes treatments (sitagliptin), gastrointestinal drugs (solifenacin, mirabegron), oncology therapies, pain management drugs, and anti-infectives (atovaquone). Additionally, they offer adapalene (used in dermatology) and rosuvastatin (a cholesterol-lowering drug).
A significant aspect of Alivus's business model is the provision of contract development and manufacturing services (CDMO). This means they produce APIs not only for their own branded formulations but also for other multinational corporations and specialty pharmaceutical companies. This CDMO segment allows them to leverage their manufacturing expertise and capacity for a broader client base, contributing to revenue diversification.
Alivus boasts a global reach, exporting its APIs to major markets including Europe, North America, Latin America, Japan, and other international destinations. This broad geographical reach underscores the company’s success in establishing itself as a significant player in the global API market.
The company, a subsidiary of Nirma Limited, was incorporated in 2011 and is headquartered in Mumbai, India. Its recent name change to Alivus Life Sciences Limited, effective December 2024, reflects a potential strategic repositioning or branding effort within the pharmaceutical industry.
COMPANY FACTS - ALIVUS
Registered Address
4th Floor, OIA House, 470, Cardinal Gracious Road, Andheri (E)
Mumbai
MAHARASHTRA
IN
Tel: 912268297979
Website:https://www.alivus.com/
Investor Relations:http://www.glenmarklifesciences.com/financial-results.php
Company Details
Group: Pharmaceuticals, Biotechnology & Life Sciences
Sector: Health Care
Industry: Pharmaceuticals
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
Employees: 2,203
IPO Date: 06/08/2021
MANAGEMENT - ALIVUS
Mr. Hiren Patel
Non-Executive Non-Independent Chairman of the Board
Dr. Yasir Rawjee
Chief Executive Officer, Managing Director, Executive Director
Mr. Tushar Mistry
Chief Financial Officer, Senior Vice President
Mr. Sumantra Mitra
Senior Vice President - Human Resources, Head - Human Resources
Mr. Navin Agrawal
Senior Vice President - Quality, Head - Corporate Quality
Mr. Mathew George
Senior Vice President - Regulatory Affairs, Head - Regulatory Affairs
Mr. Rudalf Corriea
Company Secretary, Compliance Officer
Dr. Palle Acharyulu
Group Vice President, Head - Research and Development
Mr. Vinod Naik
Head - Technical Operations, Whole Time Director
Mrs. Manju Agarwal
Non-Executive Independent Director
Mr. Taruvai Easwar
Non-Executive Independent Director
Dr. Savan Godiawala
Non-Executive Independent Director
Investor Questions Answered
Alivus Life Sciences Ltd (ALIVUS) Stock FAQs
Get answers to the most common questions about Alivus Life Sciences Ltd stock price, fundamentals, financial metrics, and investment analysis
The current share price of Alivus Life Sciences Ltd (ALIVUS) is ₹939.4. Today, the stock has declined by ₹10.35 (1.09%), trading in a range of ₹925.3 to ₹946.75. The stock opened at ₹944 with a trading volume of 25,100 shares.
Alivus Life Sciences Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹11,095.98 crores, P/E ratio of 20.35, ROE of 9.32%, and ROCE of 0.00%. The dividend yield stands at 0.55%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Alivus Life Sciences Ltd (ALIVUS) is ₹1,225.1, while the 52-week low is ₹819. Currently trading at ₹939.4, the stock is 29.6% away from its 52-week low and 23.3% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Alivus Life Sciences Ltd stock at ₹939.4 depends on multiple factors. The stock is currently trading with a P/E ratio of 20.35 and P/B ratio of N/A. Today's performance shows a loss of 1.09%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Alivus Life Sciences Ltd offers a dividend yield of 0.55%, which means for every ₹100 invested at the current price of ₹939.4, you can expect to receive approximately ₹0.55 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Alivus Life Sciences Ltd's key financial metrics include: P/E Ratio: 20.35, P/B Ratio: N/A, ROE: 9.32%, ROCE: 0.00%, Dividend Yield: 0.55%, EPS: ₹44.23, Book Value: ₹229.94, Debt-to-Equity: 0.02, and Current Ratio: N/A. The company's market cap stands at ₹11,095.98 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Alivus Life Sciences Ltd stock opened at ₹944 and is currently trading at ₹939.4, showing a decline of ₹10.35 (1.09%). The intraday high is ₹946.75 and low is ₹925.3. The trading volume stands at 25,100 shares, indicating moderate market participation today.
Alivus Life Sciences Ltd has a Price-to-Earnings (P/E) ratio of 20.35, which means investors are willing to pay ₹20.35 for every ₹1 of earnings. With an EPS of ₹44.23, this P/E ratio indicates moderate valuation in line with market standards. Compare this with industry peers and historical P/E ratios for better context.
Alivus Life Sciences Ltd has a market capitalization of ₹11,095.98 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹939.4) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Alivus Life Sciences Ltd has a book value of ₹229.94 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹939.4, which is 308.5% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Alivus Life Sciences Ltd has a Return on Equity (ROE) of 9.32% and Return on Capital Employed (ROCE) of 0.00%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Alivus Life Sciences Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Alivus Life Sciences Ltd has a debt-to-equity ratio of 0.02, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Alivus Life Sciences Ltd has an Earnings Per Share (EPS) of ₹44.23, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹939.4 and P/E ratio of 20.35, investors are paying 20.35 times the annual earnings per share. This moderate EPS suggests decent earnings generation. Track EPS growth over quarters to assess earnings momentum.
Alivus Life Sciences Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Alivus Life Sciences Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Alivus Life Sciences Ltd stock, consider: 1) Fundamental Analysis - Review P/E (20.35), ROE (9.32%), debt-to-equity (0.02), and growth rates. 2) Technical Analysis - Check 52-week range (₹819.00 - ₹1225.10), moving averages, and chart patterns. 3) Valuation - Compare current price (₹939.40) with book value (₹229.94) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Alivus Life Sciences Ltd share is ₹2.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹939.4 is 46870x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Alivus Life Sciences Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹819.00 - ₹1225.10). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.02 indicates leverage. 4) Liquidity Risk - Based on trading volume of 25,100 shares. 5) Valuation Risk - P/E of 20.35 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Alivus Life Sciences Ltd operates in the industry with key metrics: P/E ratio of 20.35, ROE of 9.32%, market cap of ₹11,095.98 crores, and dividend yield of 0.55%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.02), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Alivus Life Sciences Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹939.4, with a 52-week range of ₹819.00 to ₹1225.10. Based on fundamentals like P/E (20.35), ROE (9.32%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Alivus Life Sciences Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹939.40. 2) Fundamental Deterioration - Declining ROE (currently 9.32%), increasing debt (D/E: 0.02), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Alivus Life Sciences Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.55%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.
Menu